<DOC>
	<DOCNO>NCT02285283</DOCNO>
	<brief_summary>The purpose randomize control double-blinded trial determine addition oral antifungal typical post-operative medical therapy prevent reduce incidence recurrence nasal polyp fungal sensitive patient chronic rhinosinusitis nasal polyp ( CRSwNP ) .</brief_summary>
	<brief_title>RCT Itraconazole Fungal Sensitive Chronic Rhinosinusitis With Nasal Polyps</brief_title>
	<detailed_description>CRSwNP patient schedule medically-indicated sinus surgery undergo screen ELIspot assay identify patient fungal sensitivity base positive fungal induce IL-4 ELIspot . Enrolled fungal sensitive CRSwNP patient undergo sinus surgery randomize either placebo itraconazole 200 mg PO BID 24 week addition standardize post-surgical regimen ( 9 day perioperative prednisone , saline irrigation pain medication need ) . Patients follow outpatient rhinology clinic 48 week total . During post-op visit , compliance medication determine . Patients question possible side effect adverse event post-operative medication . Then , patient evaluate 2 nasal specific quality life questionnaire nasal endoscopy . The goal nasal endoscopy evaluate state sinus mucosa determine recurrence nasal polyp .</detailed_description>
	<mesh_term>Sinusitis</mesh_term>
	<mesh_term>Nasal Polyps</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>Meet criterion diagnosis CRS nasal polyp undergo medically indicate sinus surgery cystic fibrosis aspirin exacerbate respiratory disease uncontrolled unstable chronic disease uncontrolled diabetes active history cancer HIV positive history liver kidney disease history disease effect immune system pregnant allergy triazole antifungal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>